



# PROGRAM

## Sunday, May 25th 2025

14:00 – 16.00	Pre-conference workshop: <b>Managing Competing Priorities in BD&amp;L: Insights from Behavioral Science</b> Jeffrey Herman, Co-founder of Leadership Advisory Partners
15.30 onwards	Registration start – check-in (only from 15.00)
16.00 – 17.00	Welcome coffee & networking
17.00 – 17.15	<b>Welcome and Opening of the Swiss HLG Conference 2025</b> Sarah Holland, President Swiss HLG
17.15 – 18.00	<b>Key Note Infectious Partnerships</b> David Veitch, CEO at Basilea Pharmaceutica
18.00 – 18.45	<b>Key Note Transformational Partnerships: Crafting Deals That Drive Strategic Change</b> Konstantina Katcheves, SVP, Global Business Development for Innovative Medicines at Teva Pharmaceuticals
18.45 – 19.00	<b>Ice-breaker</b> Chris Isler and Tytus Litynski, Swiss HLG Board Members
19.00 – 21.00	Kick-off dinner
21.00 onwards	Networking with peers - venue a short walk from the hotel

## Monday, May 26th 2025

07.00	Pre-conference morning run group - voluntary (meet at reception)
08.30 – 09.00	<b>Swiss HLG General Assembly – Swiss HLG members by invitation</b>
09.00 – 09.05	Welcome & housekeeping <i>Intro - External drivers of portfolio strategy</i> Luis Vieira, Swiss HLG Board Member
09.05 – 09.40	<b>Monday Key Note: Paying for Innovation: The New Rules of Biopharma Commercialization</b> Jeffrey Berkowitz, CEO at Real Endpoints
09.40 – 10.15	<b>All Change: Why Biopharma Portfolio-builders Should Question Their Assumptions</b> Melanie Senior, Commentator on the biopharma industry

## Monday, May 26th 2024, continued

10.15 – 10.30	Group Photo in conference room on stage
10.30 – 11.00	Refreshment break & networking
11.00 – 11.30	<b>Navigating EU Pharmaceutical Legislative Change: Recent Developments and Emerging Challenges</b> Sarah Thomae, Senior Legal Counsel R&D Transactions at Novartis Pharma AG
11.30 – 12.00	<b>The New Pan-EU HTA Process: How Joint Clinical Assessments Should Feature in BD Thinking</b> Sian Tanner, Principal, Value and Payer Evidence Consulting at IQVIA
12.00 – 12.10	<b>Q&amp;A</b>
12.10 – 13.35	Lunch & networking
13.35 – 13.45	<i>Intro - Managing a sustainable portfolio through dealmaking</i> Laurence de Schoulepnikoff, Swiss HLG Board Member
13.45 – 14.30	<b>Managing a Portfolio of Minority Stakes - the View From Venture Capital</b> Karen Wagner, Managing Partner at Ysios Capital Juergen Eckhardt, Executive Vice President, Head of Pharma BD&L, Head of Leaps by Bayer
14.30 – 15.00	<b>From Project to Portfolio: Building and Shaping a Product Pipeline</b> Kelvin Stott, Founder & CEO at Amporin Pharmaceuticals AG
15.00 – 15.30	Refreshment break & networking
15.30 – 16.00	<b>Unlocking Innovation: Exploring Creative Deal Structures to Secure a Robust In-Licensing Oncology Pipeline</b> Frédéric Lévy, Chief Scientific Officer at Debiopharm International SA
16.00 – 16.45	<b>Strategic Divestment/Acquisition of Pharma Products: Optimizing Portfolio for Growth</b> Philippe Beaupere, Chief Corporate Development Officer at Substipharm Jean-Marc Séquier, Corporate Business & Development, Head of Divestments at Novartis
16.45 – 17.00	<b>Swiss HLG Start-Up Initiative</b> Michael Huebner, Swiss HLG Board Member
17.00 - 18:45	Networking and or free time
19.00	Swiss HLG networking dinner - 18.45 meet at the entrance to the reception/meet directly at restaurant Why Montreux, a short walk from the hotel
21.45 onwards	Networking with peers - meet at Mona Hotel

# PROGRAM

**Tuesday, May 27th 2024**

**The conference starts at 08.55**

07.30	Pre-conference morning run & walk group - voluntary (meet at reception)
08.55 – 09.00	<b>Welcome &amp; Housekeeping</b> <i>Intro - Navigating the unexpected: Adapting your portfolio strategy</i> Ragip Ziyal, Swiss HLG Board Member
09.00 – 09.30	<b>Genmab: A 25-year Journey From Danish Start-up to Commercial Biotech</b> Peter Louwagie, Senior Vice President of Corporate Development/M&A & BD&L at Genmab
09.30 – 10.00	<b>Pioneering DARPIn Therapeutics for Patients, with Partners – Navigating uncertainty and leveraging opportunities</b> Laura Jeanbart, Director, Head of Portfolio Management & Communications at Molecular Partners
10.00 – 10.30	<b>How to Strengthen the Path to Success - as a CDMO in a Changing Environment</b> Marianne Späne, CBO EVP Member of the Executive Committee at Siegfried
10.30 – 11.00	<b>Refreshment break &amp; networking</b>
11.00 – 11.40	<b>Key Note</b> <b>Reassessing the U.S. Landscape for Life Sciences: Implications for Deal-Making</b> Murray Aitken, Executive Director at IQVIA Institute for Human Data Science
11.40 – 12.20	<b>Closing Key Note: The Role of Business Development in Building Strategic and Resilient Portfolios</b> Isabel Afonso, CEO at Arcera Life Sciences
12.20 – 12.30	<b>Closing Remarks</b> Jean-Marc Séquier, Vice President Swiss HLG
12.30 - 13.30	<b>Farewell Lunch</b>



**BECOME A MEMBER / BECOME A SUPPORTER  
WE ARE ONLY AS STRONG AS OUR MEMBERS**

[www.swisshlg.com](http://www.swisshlg.com)

